Lilly Eyes Zepbound Label Expansion After Clearing Phase III Sleep Apnea Study
With Wednesday’s readout showing symptom improvements in obstructive sleep apnea patients, Eli Lilly is preparing to file for a label expansion for its blockbuster weight-loss drug Zepbound.